156 related articles for article (PubMed ID: 31311724)
1. Interstitial pneumonitis associated with dasatinib: two case reports and literature review.
Ito Y; Tanigawa M; Iwamoto K; Nigi A; Itani H; Kondo S; Tokui T; Usui E; Tamaki S
Respir Investig; 2019 Sep; 57(5):506-509. PubMed ID: 31311724
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.
Takekoshi D; Matsui Y; Akutsu T; Nishioka A; Kiritani A; Okuda K; Watanabe J; Miyagawa H; Utsumi H; Hashimoto M; Wakui H; Minagawa S; Hara H; Numata T; Noda Y; Makishima R; Ikegami M; Kawabata Y; Araya J; Kuwano K
Intern Med; 2020 Sep; 59(18):2297-2300. PubMed ID: 32536651
[TBL] [Abstract][Full Text] [Related]
3. Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review.
Kim SA; Kwon BS; Chung JH; Lee JY; Bang SM; Lee JO
Ther Adv Respir Dis; 2022; 16():17534666221135322. PubMed ID: 36346055
[TBL] [Abstract][Full Text] [Related]
4. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
Saydan B; Özmen D; Eşkazan AE
Expert Rev Hematol; 2024 Jul; 17(7):275-277. PubMed ID: 38888284
[No Abstract] [Full Text] [Related]
5. Dasatinib-induced loss of eyebrows.
Naithani R
Br J Haematol; 2017 Nov; 179(3):362. PubMed ID: 28737227
[No Abstract] [Full Text] [Related]
6. Dasatinib dose management for the treatment of chronic myeloid leukemia.
Talpaz M; Saglio G; Atallah E; Rousselot P
Cancer; 2018 Apr; 124(8):1660-1672. PubMed ID: 29370463
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
8. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
9. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
10. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Hoehn D; Cortes JE; Medeiros LJ; Jabbour EJ; Hidalgo JE; Kanagal-Shamanna R; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl(Suppl):S86-92. PubMed ID: 27521332
[TBL] [Abstract][Full Text] [Related]
11. Unusual case of dasatinib-associated acute bilateral hyphemas leading to blindness in a patient with chronic myeloid leukaemia.
Sharma S; Garg N; Ghiuzeli CM
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30150345
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
14. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
[TBL] [Abstract][Full Text] [Related]
15. [Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].
Makeeva LM; Emelina EI; Gendlin GE; Nikitin IG; Vasyuk YA; Nesvetov VV
Kardiologiia; 2017 Apr; 57(S4):53-60. PubMed ID: 29466183
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
17. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
18. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Latagliata R; Stagno F; Annunziata M; Abruzzese E; Iurlo A; Guarini A; Fava C; Gozzini A; Bonifacio M; Sorà F; Leonetti Crescenzi S; Bocchia M; Crugnola M; Castagnetti F; Capodanno I; Galimberti S; Feo C; Porrini R; Pregno P; Rizzo M; Antolino A; Mauro E; Sgherza N; Luciano L; Tiribelli M; Russo Rossi A; Trawinska M; Vigneri P; Breccia M; Rosti G; Alimena G
Neoplasia; 2016 Sep; 18(9):536-40. PubMed ID: 27659013
[TBL] [Abstract][Full Text] [Related]
19. Interstitial pneumonitis during imatinib therapy.
Isshiki I; Yamaguchi K; Okamoto S
Br J Haematol; 2004 May; 125(4):420. PubMed ID: 15142112
[No Abstract] [Full Text] [Related]
20. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP; Wallis N; Farber HW; Mauro MJ; Wolf RA; Mattei D; Guha M; Rea D; Peacock A
Am J Hematol; 2015 Nov; 90(11):1060-4. PubMed ID: 26284693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
